256 related articles for article (PubMed ID: 34756527)
21. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
22. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
24. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
Sun SX; Kuerer HM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):804-805. PubMed ID: 31654165
[No Abstract] [Full Text] [Related]
25. [Primary systemic therapy in breast cancer patients (2007-2010)].
Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
[TBL] [Abstract][Full Text] [Related]
26. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.
Mukai H; Arihiro K; Shimizu C; Masuda N; Miyagi Y; Yamaguchi T; Yoshida T
Breast Cancer; 2016 Jan; 23(1):73-77. PubMed ID: 26423822
[TBL] [Abstract][Full Text] [Related]
27. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
van la Parra RFD; Tadros AB; Checka CM; Rauch GM; Lucci A; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
Br J Surg; 2018 Apr; 105(5):535-543. PubMed ID: 29465744
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
29. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
30. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study.
van Deurzen CH
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):627-633. PubMed ID: 27590331
[TBL] [Abstract][Full Text] [Related]
32. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
[TBL] [Abstract][Full Text] [Related]
33. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
34. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
35. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
36. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
37. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.
Lim LY; Miao H; Lim JS; Lee SC; Bhoo-Pathy N; Yip CH; Taib NA; Chan P; Tan EY; Lim SH; Lim GH; Woo E; Tan YS; Lee JA; Wong M; Tan PH; Ong KW; Wong FY; Yap YS; Hartman M
Cancer Med; 2017 Jan; 6(1):173-185. PubMed ID: 28000426
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
39. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
[TBL] [Abstract][Full Text] [Related]
40. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
